Alzheimer's Association Webinar

A scientific focused discussion on recent late stage trial readouts, the broader treatment landscape and considerations for research and clinical communities. The goal of this session (as well as past and future similar sessions) is to foster communication and conversation among the scientific community. This also includes a conversation about clinical meaningfulness and safety, among other topics. Lastly, we discuss the future for the clinical community and the guidance needed for the immediate and longer term.

Session Outline**:

• Welcome Remarks
• Biology Behind the Approach & Target Engagement
• Topline Results from Recent Announcements
• Clinical Meaningfulness and What Does this Mean
• Path Forward: Landscape and Future
• Question & Answer

Panelists include**: Maria C. Carrillo, Ronald Petersen, Dennis Selkoe, Liana Apostolova, Stephen Salloway, Paul Aisen, Gil Rabinovici, Alireza Atri and Marwan Sabbagh

**Individual speakers' conflicts of interest will be shared during the discussion.

The Alzheimer’s Association forges partnerships with all those with the shared commitment to end Alzheimer’s and other dementia, including Alzheimer’s organizations around the globe, the National Institutes of Health, National Institute on Aging, universities, corporations and the pharmaceutical, biotech and device industries. With our broad partnerships, we are committed to transparency. The Alzheimer’s Association received 0.70 percent of its total 2021 contributed revenue from the biotechnology, pharmaceutical, diagnostics, and clinical research industries. This and additional information can be found at www.alz.org/about/transparency. Hosted by the Alzheimer's Association.